- Home
- FORA vs EYEN Comparison
FORA vs EYEN Comparison
Compare FORA & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- EYEN
- Stock Information
- Founded
- FORA 2014
- EYEN 2014
- Country
- FORA United States
- EYEN United States
- Employees
- FORA N/A
- EYEN N/A
- Industry
- FORA Computer Software: Prepackaged Software
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- EYEN Health Care
- Exchange
- FORA Nasdaq
- EYEN Nasdaq
- Market Cap
- FORA 63.8M
- EYEN 38.2M
- IPO Year
- FORA N/A
- EYEN 2018
- Fundamental
- Price
- FORA $2.10
- EYEN $0.55
- Analyst Decision
- FORA Strong Buy
- EYEN Strong Buy
- Analyst Count
- FORA 1
- EYEN 2
- Target Price
- FORA $5.00
- EYEN $12.00
- AVG Volume (30 Days)
- FORA 14.2K
- EYEN 879.0K
- Earning Date
- FORA 11-07-2024
- EYEN 11-11-2024
- Dividend Yield
- FORA N/A
- EYEN N/A
- EPS Growth
- FORA N/A
- EYEN N/A
- EPS
- FORA 0.06
- EYEN N/A
- Revenue
- FORA $20,371,880.00
- EYEN $31,405.00
- Revenue This Year
- FORA N/A
- EYEN $50,309.30
- Revenue Next Year
- FORA $10.64
- EYEN $421.63
- P/E Ratio
- FORA $36.34
- EYEN N/A
- Revenue Growth
- FORA 6.97
- EYEN N/A
- 52 Week Low
- FORA $2.00
- EYEN $0.37
- 52 Week High
- FORA $4.15
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- FORA 38.13
- EYEN 52.60
- Support Level
- FORA $2.05
- EYEN $0.52
- Resistance Level
- FORA $2.16
- EYEN $0.59
- Average True Range (ATR)
- FORA 0.05
- EYEN 0.05
- MACD
- FORA 0.00
- EYEN 0.01
- Stochastic Oscillator
- FORA 31.77
- EYEN 66.45
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.